Daniel J. Moorhead Sells 10,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $7.68, for a total transaction of $76,800.00. Following the transaction, the chief financial officer now directly owns 19,738 shares in the company, valued at $151,587.84. This trade represents a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Zynex Trading Down 1.4 %

Shares of Zynex stock opened at $7.73 on Tuesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a market capitalization of $246.20 million, a P/E ratio of 51.53 and a beta of 0.54. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The company’s fifty day moving average is $8.11 and its two-hundred day moving average is $8.20.

Hedge Funds Weigh In On Zynex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Congress Asset Management Co. grew its stake in Zynex by 4.7% in the 4th quarter. Congress Asset Management Co. now owns 121,450 shares of the company’s stock worth $973,000 after acquiring an additional 5,405 shares during the period. Investment Partners Asset Management Inc. boosted its holdings in shares of Zynex by 10.4% during the fourth quarter. Investment Partners Asset Management Inc. now owns 12,942 shares of the company’s stock worth $104,000 after purchasing an additional 1,220 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Zynex in the fourth quarter valued at $26,000. Janney Montgomery Scott LLC increased its stake in Zynex by 10.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company’s stock valued at $1,276,000 after purchasing an additional 14,820 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Zynex by 3.3% during the third quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company’s stock worth $334,000 after buying an additional 1,318 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on ZYXI. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Zynex in a research note on Friday, December 6th. Royal Bank of Canada decreased their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.